AbbVie (ABBV) Revenue (2012 - 2026)

AbbVie has disclosed Revenue across 15 years of filings, most recently posting $15.0 billion for Q1 2026.

• In Q1 2026, Revenue rose 12.43% year-over-year to $15.0 billion; the TTM figure through Mar 2026 stood at $62.8 billion (up 9.5% YoY), while the FY2025 annual figure was $61.2 billion, up 8.57% from the prior year.
• Revenue declined to $15.0 billion in Q1 2026, from $16.6 billion in the prior quarter.
• Over the last five years, Revenue for ABBV reached as high as $16.6 billion in Q4 2025 and fell as low as $12.2 billion in Q1 2023.
• The 5-year median for Revenue is $14.5 billion (2024), against an average of $14.4 billion.
• Annual changes were most pronounced in 2023 — Revenue fell 9.7% — and 2026, when it gained 12.43%.
• A 5-year view of Revenue shows it stood at $15.1 billion in 2022, then slipped by 5.42% to $14.3 billion in 2023, then climbed by 5.6% to $15.1 billion in 2024, then rose by 10.04% to $16.6 billion in 2025, then fell by 9.72% to $15.0 billion in 2026.
• According to Business Quant data, Revenue over the past three periods registered $15.0 billion, $16.6 billion, and $15.8 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.